These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study. Advani K; Batra M; Tajpuriya S; Gupta R; Saraswat A; Nagar HD; Makwana L; Kshirsagar S; Kaul P; Ghosh AK; Pradhan S; Mehta A; Jaiswal A; Nakhate KT; Kamdi S J Obstet Gynaecol; 2020 Jan; 40(1):96-101. PubMed ID: 31339394 [TBL] [Abstract][Full Text] [Related]
5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2. Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ; Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102 [TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824 [TBL] [Abstract][Full Text] [Related]
7. The frequency of insulin resistance calculated upon the basis of a fasting glucose to insulin ratio and characteristics of insulin resistant women with polycystic ovary syndrome. Popovska-Dimova Z; Krstevska B Prilozi; 2006 Jul; 27(1):87-95. PubMed ID: 16985482 [TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities. Elkind-Hirsch KE Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059 [TBL] [Abstract][Full Text] [Related]
9. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Stepto NK; Cassar S; Joham AE; Hutchison SK; Harrison CL; Goldstein RF; Teede HJ Hum Reprod; 2013 Mar; 28(3):777-84. PubMed ID: 23315061 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728 [TBL] [Abstract][Full Text] [Related]
11. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776 [TBL] [Abstract][Full Text] [Related]
12. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. Genazzani AD; Shefer K; Della Casa D; Prati A; Napolitano A; Manzo A; Despini G; Simoncini T J Endocrinol Invest; 2018 May; 41(5):583-590. PubMed ID: 29090431 [TBL] [Abstract][Full Text] [Related]
13. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Bozdag G; Mumusoglu S; Zengin D; Karabulut E; Yildiz BO Hum Reprod; 2016 Dec; 31(12):2841-2855. PubMed ID: 27664216 [TBL] [Abstract][Full Text] [Related]
14. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS]. Cappelli V; Di Sabatino A; Musacchio MC; De Leo V Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942 [TBL] [Abstract][Full Text] [Related]
16. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. Azziz R J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211 [TBL] [Abstract][Full Text] [Related]
17. Body Composition, Metabolic Characteristics, and Insulin Resistance in Obese and Nonobese Women with Polycystic Ovary Syndrome. Satyaraddi A; Cherian KE; Kapoor N; Kunjummen AT; Kamath MS; Thomas N; Paul TV J Hum Reprod Sci; 2019; 12(2):78-84. PubMed ID: 31293320 [TBL] [Abstract][Full Text] [Related]
18. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index. Genazzani AD; Battipaglia C; Petrillo T; Piacquadio N; Ambrosetti F; Arnesano M; Semprini E; Sponzilli A; Tomatis V; Simoncini T Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584 [No Abstract] [Full Text] [Related]
19. Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women. Anaforoglu I; Algun E; Incecayir O; Ersoy K Metab Syndr Relat Disord; 2011 Oct; 9(5):375-80. PubMed ID: 21657888 [TBL] [Abstract][Full Text] [Related]
20. The role of a pulse-based diet on infertility measures and metabolic syndrome risk: protocol of a randomized clinical trial in women with polycystic ovary syndrome. McBreairty LE; Chilibeck PD; Chizen DR; Pierson RA; Tumback L; Sherar LB; Zello GA BMC Nutr; 2017; 3():23. PubMed ID: 32153805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]